A Study of (Interleukin-12) IL-12 in Patients With Acute Myelogenous Leukemia (AML)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02483312|
Recruitment Status : Unknown
Verified April 2021 by University Health Network, Toronto.
Recruitment status was: Recruiting
First Posted : June 26, 2015
Last Update Posted : April 19, 2021
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
This is a phase 1 study (the first stage in testing a new treatment to see how safe and tolerable the treatment is) which will include patients with acute myeloid leukemia (AML) that has either returned or has a more than a 70% chance of coming back and cannot have a bone marrow transplant.
This study will see whether modifying a patient's AML cells to produce IL-12 and giving it back to the patient is safe and useful in patients with AML that cannot have bone marrow transplants.
|Condition or disease||Intervention/treatment||Phase|
|Acute Myeloid Leukemia||Biological: IL-12||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||9 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase I Study of Autologous Acute Myelogenous Leukemia (AML) Cells Containing Lentivirus Engineering Expression of IL-12|
|Study Start Date :||September 2015|
|Estimated Primary Completion Date :||August 2021|
|Estimated Study Completion Date :||February 2022|
A single dose of IL-12, given intravenously.
- Number of side effects by type and severity [ Time Frame: 2 years ]
- Levels of IL-12 [ Time Frame: 1 day ]
- Levels of acute myeloid leukemia (AML) [ Time Frame: 1 day ]
- Length of time patient is alive [ Time Frame: 2 years ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Patient with AML and >=18 years of age.
- Agrees to participate in the study and signs the informed consent
- Viable cells are available for successful modification
- First or higher complete remission and have high risk features of relapse.
- Patients who have received prior treatment and are not in remission must have stable white blood cell count and are not receiving any chemotherapy or desiring further intensive treatment.
- Less than 10% blast cells in the bone marrow following induction or re-induction therapy and not desiring further intensive treatment.
- Acceptable creatinine, Aspartate transaminase (AST), Alkaline phosphatase (ALP), bilirubin lab results.
- Agree to use contraception
- Not pregnant
- Able to comply with study procedures
- Eastern Cooperative Oncology Group (ECOG) performance status >2
- Known persistent infection
- Known central nervous system (CNS) disease
- Greater than 10% blasts in the bone marrow or circulating blast cells
- Life expectancy < 2 months
- Receiving any chemotherapy, corticosteroids, Cox2 inhibitors or any non-drug therapies with the intent of altering the immune response or kill leukemic cells within one week prior to infusion of IL-12, except azacytidine.
- Patients who are HIV positive.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02483312
|Contact: Mark Minden, M.D.||416-946-2838|
|Princess Margaret Centre Centre||Recruiting|
|Toronto, Ontario, Canada, M5G 2M9|
|Contact: Mark Minden, M.D. 416-946-2838|
|Principal Investigator: Mark Minden, M.D.|
|Principal Investigator:||Mark Minden, M.D.||Princess Margaret Cancer Centre|
|Responsible Party:||University Health Network, Toronto|
|Other Study ID Numbers:||
OZM-068 ( Other Identifier: Ozmosis Research Inc. )
|First Posted:||June 26, 2015 Key Record Dates|
|Last Update Posted:||April 19, 2021|
|Last Verified:||April 2021|
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type